# A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC

Source: https://onco.cc/trials/nct06663137/  
OnCo record `nct06663137` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Docetaxel and Gemcitabine in bladder & urothelial cancer, run by Relmada Therapeutics, Inc., now recruiting.

## Summary

A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC is a phase 2 interventional study registered as NCT06663137 by Relmada Therapeutics, Inc., with 70 participants planned, started 2024-08-01 and due to reach its primary completion in 2027-11. Interventions recorded: NDV01 intravesical controlled release formulation of gemcitabine and docetaxel.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06663137
- Phase: 2
- Setting: A Single-Center, Open Label, Single Arm Study, to Evaluate the Safety and Efficacy of NDV-01 KIT in Participants With Non Muscle Invasive Bladder Cancer (NMIBC)
- Sponsor: Relmada Therapeutics, Inc.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06663137: https://clinicaltrials.gov/study/NCT06663137

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct06663137.json